Home » Stocks » Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. (IOVA)

Stock Price: $36.98 USD -0.88 (-2.32%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $37.00 +0.02 (0.05%) Oct 21, 5:05 PM

Stock Price Chart

Key Info

Market Cap 5.42B
Revenue (ttm) n/a
Net Income (ttm) -245.67M
Shares Out 146.44M
EPS (ttm) -1.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $36.98
Previous Close $37.86
Change ($) -0.88
Change (%) -2.32%
Day's Open 38.02
Day's Range 36.40 - 38.04
Day's Volume 1,292,679
52-Week Range 18.70 - 41.49

More Stats

Market Cap 5.42B
Enterprise Value 4.65B
Earnings Date (est) Oct 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 146.44M
Float 137.13M
EPS (basic) -1.93
EPS (diluted) -1.93
FCF / Share -1.56
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 12.92M
Short Ratio 10.94
Short % of Float 9.42%
Beta 0.96
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.96
Revenue n/a
Operating Income -251.16M
Net Income -245.67M
Free Cash Flow -208.20M
Net Cash 769.53M
Net Cash / Share 5.25
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -25.05%
ROE -42.51%
ROIC -68.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (12)

Buy 10
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(18.74% upside)
Current: $36.98
Target: 43.91
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-207-128-92.88-53.64-27.86-12.04-22.64-8.13-21.22-0.82
Net Income-198-124-92.06-52.89-27.66-12.04-25.38-3.31-25.69-1.61
Shares Outstanding12497.2865.2455.2744.4124.999.760.800.760.65
Earnings Per Share-1.59-1.27-1.41-1.85-0.62-0.48-3.47-4.14-34.00-2.00
Operating Cash Flow-159-101-78.71-32.67-18.38-8.63-3.66-2.24-6.19-0.62
Capital Expenditures-6.92-1.20-1.03-1.52-1.14-1.59-0.01--0.03-
Free Cash Flow-166-102-79.74-34.19-19.52-10.23-3.67-2.24-6.22-0.62
Cash & Equivalents31346914516610444.9119.670.010.511.29
Total Debt11.50------6.485.00-
Net Cash / Debt30146914516610444.9119.67-6.48-4.491.29
Book Value29946614516710444.8517.60-11.32-12.780.64
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Iovance Biotherapeutics, Inc.
Country United States
Employees 148
CEO Maria Fardis

Stock Information

Ticker Symbol IOVA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IOVA


Iovance Biotherapeutics, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations. Iovance Biotherapeutics, Inc. has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Ohio State University, and MedImmune; and research collaboration with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.